1. Home
  2. ASA vs LIMN Comparison

ASA vs LIMN Comparison

Compare ASA & LIMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASA
  • LIMN
  • Stock Information
  • Founded
  • ASA 1958
  • LIMN 2018
  • Country
  • ASA United States
  • LIMN United States
  • Employees
  • ASA N/A
  • LIMN N/A
  • Industry
  • ASA Precious Metals
  • LIMN
  • Sector
  • ASA Industrials
  • LIMN
  • Exchange
  • ASA Nasdaq
  • LIMN NYSE
  • Market Cap
  • ASA 622.9M
  • LIMN 623.8M
  • IPO Year
  • ASA N/A
  • LIMN N/A
  • Fundamental
  • Price
  • ASA $31.11
  • LIMN $5.93
  • Analyst Decision
  • ASA
  • LIMN
  • Analyst Count
  • ASA 0
  • LIMN 0
  • Target Price
  • ASA N/A
  • LIMN N/A
  • AVG Volume (30 Days)
  • ASA 81.9K
  • LIMN 987.0K
  • Earning Date
  • ASA 08-12-2025
  • LIMN 01-01-0001
  • Dividend Yield
  • ASA 0.19%
  • LIMN N/A
  • EPS Growth
  • ASA N/A
  • LIMN N/A
  • EPS
  • ASA 14.01
  • LIMN N/A
  • Revenue
  • ASA $3,923,667.00
  • LIMN N/A
  • Revenue This Year
  • ASA N/A
  • LIMN N/A
  • Revenue Next Year
  • ASA N/A
  • LIMN N/A
  • P/E Ratio
  • ASA $2.21
  • LIMN N/A
  • Revenue Growth
  • ASA 45.39
  • LIMN N/A
  • 52 Week Low
  • ASA $17.42
  • LIMN $4.40
  • 52 Week High
  • ASA $35.00
  • LIMN $33.66
  • Technical
  • Relative Strength Index (RSI)
  • ASA 40.46
  • LIMN N/A
  • Support Level
  • ASA $30.95
  • LIMN N/A
  • Resistance Level
  • ASA $32.56
  • LIMN N/A
  • Average True Range (ATR)
  • ASA 0.87
  • LIMN 0.00
  • MACD
  • ASA -0.25
  • LIMN 0.00
  • Stochastic Oscillator
  • ASA 4.52
  • LIMN 0.00

About ASA ASA Gold and Precious Metals Limited

ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.

About LIMN LIMINATUS PHARMA INC

Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.

Share on Social Networks: